萬邦德(002082.SZ):子公司自毀式注射器通過美國FDA 510 (K)審核
格隆匯2月16日丨萬邦德(002082.SZ)公佈,近日,公司控股子公司浙江康康醫療器械股份有限公司(“康康醫療”)收到U.S. Food and DrugAdministration(美國食品藥品監督管理局,“美國FDA”)通知,康康醫療一次性使用無菌自毀式注射器(“自毀式注射器”)正式通過美國FDA 510(K)的審核。
公司自毀式注射器產品通過美國FDA 510 (K)的審核,標誌着康康醫療生產的一次性使用無菌自毀式注射器獲得了美國市場準入資格,有利於進一步增加公司產品開拓國際市場的綜合競爭力,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.